IpamorelinAlso known as: NNC 26-0161

Mechanism of Action

Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at GHS-R1a — the ghrelin receptor expressed on somatotroph cells in the anterior pituitary. When Ipamorelin binds GHS-R1a, it triggers a signaling cascade involving phospholipase C, IP3, and intracellular calcium release that culminates in the exocytosis of stored growth hormone granules.

What separates Ipamorelin from first- and second-generation GHRPs (GHRP-6, GHRP-2, Hexarelin) is its binding selectivity. Older GHRPs activated GHS-R1a but also had meaningful affinity for CD36 and other ghrelin receptor subtypes expressed in the hypothalamus and adrenal cortex, producing dose-dependent increases in cortisol, prolactin, and appetite. Ipamorelin's binding profile is far more selective — at doses up to 200mcg, cortisol and prolactin increases are negligible in most users.

Unlike CJC-1295 (a GHRH analog that tells the pituitary to make more GH), Ipamorelin acts more like a trigger — it initiates the release of GH that has already been synthesized. Together, GHRH signaling increases the GH pool while GHRP signaling amplifies the release pulse amplitude.

Dosing Protocols

Ipamorelin has a short half-life of approximately 2 hours and must be dosed multiple times daily to maintain elevated GH pulsatility. The standard clinical and research dosing range is 100–300mcg per injection.

Standard Protocol (2x Daily)

• Morning: 100–200mcg subcutaneously, fasted or 2+ hours after eating
• Bedtime: 100–200mcg subcutaneously, 30–60 minutes before sleep

Optimized Protocol (3x Daily)

• Morning (fasted): 100–200mcg
• Post-workout: 100–200mcg, at least 90 minutes after last meal
• Bedtime: 200–300mcg

Cycle Length

Most protocols run 12–24 weeks. Some practitioners recommend a 5-day on / 2-day off pattern (skipping weekends) to prevent GHS-R1a desensitization, though this is debated. Continuous use for 6 months is common at research doses without evidence of receptor downregulation in published studies.

The CJC-1295 + Ipamorelin Stack

This is the most widely used peptide combination in hormone optimization. The synergy is mechanistic: CJC-1295 increases the amplitude and duration of GHRH signaling (boosting GH synthesis), while Ipamorelin amplifies the pulsatile release trigger (boosting GH secretion). The combination produces GH pulses significantly larger than either agent alone.

Classic Stack Protocol

• CJC-1295 (no DAC / Mod GRF 1-29): 100mcg per injection
• Ipamorelin: 100–200mcg per injection
• Timing: Same syringe or back-to-back injections, 2–3x daily
• Fasting: Minimum 2 hours post-meal

Why CJC-1295 No-DAC vs DAC?

CJC-1295 with DAC extends the half-life to 6–8 days via covalent albumin binding, providing a sustained background GH elevation. When stacked with Ipamorelin (dosed 2–3x daily), the DAC version maintains a steady-state GHRH level on which Ipamorelin creates pulsatile spikes. This is theoretically less physiologic but more convenient. CJC-1295 no-DAC must be injected at the same time as Ipamorelin and has a 30-minute half-life, preserving natural pulsatility more closely.

Effects and Benefits

Ipamorelin's effects are downstream consequences of elevated GH and IGF-1. Unlike exogenous HGH, endogenous GH stimulated by Ipamorelin maintains pulsatility and is regulated by natural negative feedback — this is considered physiologically safer and avoids the side effects associated with supraphysiologic HGH doses.

Body Composition

Elevated GH increases lipolysis (fat breakdown) by stimulating hormone-sensitive lipase and promoting fatty acid oxidation. IGF-1 increases protein synthesis and satellite cell activation, supporting lean mass accrual. Most users report gradual, lean body composition improvements over 8–16 weeks rather than dramatic acute changes.

Recovery and Sleep

GH is primarily secreted during slow-wave sleep (stage 3 NREM). Bedtime Ipamorelin dosing amplifies this natural pulse, increasing total overnight GH output. Most users report improved sleep depth, faster physical recovery between training sessions, and reduced joint discomfort within 4–6 weeks of starting.

Anti-Aging and Longevity

GH and IGF-1 decline progressively after age 30 (somatopause). Ipamorelin partially restores GH secretion toward youthful levels without the risks of exogenous HGH. Benefits in older populations include improved skin thickness, collagen synthesis, bone mineral density support, and cognitive function maintenance — effects consistent with GH's role in tissue homeostasis.

Side Effects and Safety

Ipamorelin is among the best-tolerated peptides in clinical use, largely due to its receptor selectivity. Adverse effects are generally dose-dependent and transient.

Common (Dose-Dependent)

• Water retention: Mild edema in extremities, usually resolves within 2–4 weeks as the body adapts
• Injection site irritation: Transient redness or itching at subcutaneous injection site
• Flushing/tingling: Brief warm sensation or skin tingling immediately post-injection, more common at higher doses
• Headache: Occasional, usually related to rapid GH release and transient hypoglycemia

Rare

• Insulin resistance: GH is a counter-regulatory hormone to insulin. Monitor fasting glucose at higher doses, particularly in pre-diabetic individuals.
• Carpal tunnel symptoms: Water retention in the carpal tunnel at high doses. Reduce dose if wrist numbness occurs.

What Ipamorelin Does NOT Cause

Unlike GHRP-6 and GHRP-2, Ipamorelin at standard doses does not cause significant increases in cortisol, prolactin, or hunger. This is its primary clinical advantage and the reason it has largely replaced older GHRPs in optimization protocols.

Sourcing and Quality Verification

Ipamorelin purity varies dramatically between suppliers. The peptide bond at D-2-Naphthylalanine (position 3) is a common site for degradation or substitution in lower-quality manufacturing. Biological activity is highly dependent on the D-amino acid configuration at positions 3 and 4 — L-amino acid substitutions (easier to synthesize) produce significantly lower GHS-R1a binding affinity.

What to Look For in a COA

• HPLC purity: minimum 98%, ideally 99%+
• Mass spectrometry confirmation of correct molecular weight (711.86 g/mol)
• Endotoxin testing (LAL assay): <2 EU/mg
• Sterility testing for injectable preparations

See our complete COA reading guide for how to verify every item on a Certificate of Analysis.

Frequently Asked Questions